News & Analysis on Clinical Trial Services & Contract Research And Development
Australian company pSivida is on the brink of starting clinical trials of a silicon-based nanomaterial that could find broad applications across drug and vaccine delivery, diagnostics and tissue engineering, writes Phil Taylor.
A new approach to treating obesity that destroys fat tissue using a targeted peptide drug has shown promising results in mice and will move on to non-human primate studies this summer, reports Phil Taylor.
A clear legal basis has been established for the first time which will enable research institutions to use molecular biology techniques for which provate companies have dominant patent positions without signing away the rights to their research.
Cobra Biomanufacturing of the UK saw its losses halve in the first half of the current fiscal year, in the face of continuing declines in the market for contract manufacturing of plasmid DNA.
Phylonix has been awarded a grant approaching $1 million (€815,000) by the US National Cancer Institute to develop an assay for apoptosis using zebrafish suitable for high throughput drug screening.
Germany's Xerion Pharmaceuticals has discovered a protein that seems to be intrinsically involved in the spread of cancers and could be a new target for drug therapies. The finding is also a validation of the firm's Xstream drug screening technology.
Canadian company MIV Therapeutics has been awarded a US patent for a coating technology for medical devices and drug encapsulation based on hydroxyapatite, one of the major constituents of bone.
Microbiology specialist Oxoid has launched a new soya-based media that is designed for use in media fill trials in the pharmaceutical industry.
Human clinical trials involving an Ebola vaccine took a step closer after Dutch biotechnology firm Crucell announced a single dose of its Ebola vaccine had successfully protected monkeys during trial tests.